歡迎您來到深圳欣博盛生物科技有限公司網(wǎng)站!
慢性腎病(Chronic kidney disease,CKD)目前成為了一個主要的公共衛(wèi)生問題,有越來越多的成年人患有CKD。多年來,針對這種疾病進行了大量研究,但仍需要改進治療方法并識別和/或預測患者預后結(jié)果。已經(jīng)確定在腎臟疾病中起重要作用的一種蛋白質(zhì)是腎損傷分子-1 (KIM-1)。KIM-1是一種30KDa的I型膜蛋白,具有包含免疫球蛋白(Ig)和高度O-糖基化粘蛋白亞結(jié)構(gòu)域以及多個N-糖基化位點的胞外域。它是損傷腎臟近端小管中最高度上調(diào)的蛋白質(zhì)。它在正常腎臟中以非常低的水平存在,但會在損傷期間上調(diào),在多種疾病的尿液中可檢測到。KIM-1可能是腎損傷的生物標志物,這表明它在各種腎臟疾病中具有重要意義,例如慢性腎臟疾病,以及急性腎小管壞死和急性腎衰竭。
Enzo Life Sciences提供的KIM-1 (human) ELISA kit可定量檢測人尿液樣本中的早期腎損傷生物標志物KIM-1,超高靈敏度,可檢測低至1.279 pg/ml的KIM-1。
產(chǎn)品信息
產(chǎn)品貨號 | ADI-900-226-0001 |
產(chǎn)品名稱 | KIM-1 (human) ELISA kit |
規(guī)格 | 96 wells |
其他名稱 | Kidney injury molecule-1, T-cell immunoglobulin and mucin domain-containing protein 1, TIMD-1, TIM-1, HAVCR1, Hepatitis A virus cellular receptor 1, T-cell immunoglobulin mucin receptor 1, CD365 |
靈敏度 | 1.279 pg/ml |
檢測范圍 | 7.813 - 500 pg/ml |
適用樣本類型 | 尿液 |
適用種屬 | 人 |
檢測時間 | <2 hours |
檢測波長 | 450 nm |
交叉反應 | No cross reactivity to similar molecules (< 0.02% TIM-3, TIM-4) |
試劑盒組分 | Microtiter Plate, Assay Buffer, Standard, Antibody-conjugate, Streptavidin-HRP, TMB Substrate, Stop Solution, Wash Buffer Concentrate |
標準曲線示例
部分產(chǎn)品文獻引用
1. Identification of Pre-Renal and Intrinsic Acute Kidney Injury by Anamnestic and Biochemical Criteria: Distinct Association with Urinary Injury Biomarke: S.M. Sancho-Martínez, et al.; Int. J. Mol. Sci. 24, 1826 (2023)
2. Early Diagnosis of Kidney Damage Associated with Tobacco Use: Preventive Application: J. Tascón, et al.; J. Pers. Med. 12, 1032 (2022)
3. The effect of interval and continuous work on markers of acute kidney injury in a hot environment: J. Houck, et al.; Eur. J. Appl. Physiol. 122, 2437 (2022)
4. The Effects of Beverage Intake after Exhaustive Exercise on Organ Damage, Inflammation and Oxidative Stress in Healthy Males: T. Tominaga, et al.; Antioxidants (Basel) 10, 866 (2021), Application(s): KIM-1 quantification on human urine and plasma samples
5. Biomarkers in the prediction of contrast media induced nephropathy – the BITCOIN study: F.S. Seibert, et al.; PLoS One 15, e0234921 (2020)
6. Designing new diagnostic systems for the early detection of tobacco-associated chronic renal damage in patients of a primary care centre in Salamanca, Spain: an observational, prospective study protocol: M. Prieto, et al.; BMJ Open 10, e032918 (2020)
7. Quercetin, a promising clinical candidate for the prevention of contrast-induced nephropathy: L. Vicente-Vicente, et al.; Int. J. Mol. Sci. 20, 4961 (2019), Application(s): ELISA using human urine
8. Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease: F.S. Seibert, et al.; Kidney Blood Press Res. 43, 1255 (2018)
9. Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy: J. Neuhaus, et al.; Kidney Blood Press Res. 43, 1563 (2018)
10. Hepatic ischemia/reperfusion injury associates with acute kidney injury in liver transplantation: prospective cohort study: I. Jochmans, et al.; Liver Transpl. 23, 634 (2017), Application(s): ELISA using human urine
11. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury: J.H. Westhoff, et al.; Eur. J. Pediatr. 176, 745 (2017), Application(s): ELISA using human urine
詳情請聯(lián)系Enzo Life Sciences中國授權(quán)代理-欣博盛生物